Ken Song, M.D., most recently served as President and Chief Executive Officer and board director at RayzeBio from company launch in July 2020 through the $350M+ IPO in September 2023 and the $4.1B acquisition by BMS in February 2024. Dr. Song is the co-founder and has served as the chairman of the board of directors of Ablaze Pharmaceuticals Inc. since April 2021. Previously, Dr. Song served as president, chief executive officer and board director of Metacrine, Inc., a privately-held clinical-stage biopharmaceutical company during his tenure, from September 2016 until June 2020. From April 2010 until April 2016, he served as chief executive officer of Ariosa Diagnostics, a privately-held diagnostics company that he co-founded, which was subsequently acquired by Roche. Dr. Song served as executive chairman of the board of directors of Omniome, Inc., a private life science tools company, from April 2017 until September 2021, which was subsequently acquired by Pacific Biosciences. Dr. Song served as a venture capitalist at Venrock from 2007 until 2010 and a consultant at McKinsey & Company, a management consulting company, from 2000 until 2002. Dr. Song received a B.S. in biology from Massachusetts Institute of Technology and an M.D. from University of California, San Francisco. He trained in internal medicine at the University of California, San Francisco, and specialized in gastroenterology and hepatology at the University of Washington, and was a scientific research fellow at the Fred Hutchinson Cancer Center.